Gilead Sciences: Cash-Rich HIV Leader Banking on Oncology Pipeline for Durable Growth
Overview
Gilead Sciences, Inc. is a biopharmaceutical powerhouse with a storied history in virology, anchored by its dominant, cash-generating HIV franchise. The company's strategy hinges on redeploying HIV-driven profits into high-potential oncology and inflammation pipelines. While the HIV business continues to deliver substantial and stable revenue, the long-term investment debate centers on whether growth in the newer segments can outpace declining HIV exclusivity. The diversified pipeline, recent clinical advances (notably with Trodelvy), and a seemingly discounted valuation relative to potential upside, set the stage for value realization if execution is strong.